Company Overview of Novo Nordisk, Inc.
Novo Nordisk, Inc. operates as a healthcare company that focuses on diabetes care. The company provides diabetes pharmaceuticals and insulin delivery systems. It also specializes in hemophilia care, growth hormone therapy, and hormone replacement therapy. The company was incorporated in 1982 and is headquartered in Princeton, New Jersey. It has a manufacturing facility in Clayton, North Carolina; and a research and development center in Seattle, Washington. Novo Nordisk, Inc. operates as a subsidiary of Novo Nordisk A/S.
100 College Road West
Princeton, NJ 08540
Founded in 1982
Key Executives for Novo Nordisk, Inc.
President & Executive VP of North America Operations
Senior Vice President of Finance & Operations
Chief Executive Officer of Novo Nordisk A/S and President of Novo Nordisk A/S
VP & Chief Compliance Officer
Compensation as of Fiscal Year 2017.
Novo Nordisk, Inc. Key Developments
Novo Nordisk Receives FDA Approval of OZEMPIC® (semaglutide) Injection for the Treatment of Adults with Type 2 Diabetes
Dec 5 17
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for OZEMPIC® (semaglutide) injection 0.5 mg or 1 mg, a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. OZEMPIC® is administered once weekly, on the same day each week, and can be taken any time of the day, with or without meals. The approval of OZEMPIC® is based on the results from a Phase 3a clinical trial program. In people with type 2 diabetes, OZEMPIC® showed clinically meaningful and statistically significant reductions in A1c compared with placebo, sitagliptin and exenatide extended-release. As a secondary endpoint in the trials, treatment with OZEMPIC® resulted in reductions in body weight. The most common adverse reactions reported in =5% of patients treated with OZEMPIC® are: nausea, vomiting, diarrhea, abdominal pain and constipation. OZEMPIC® is approved for use in two therapeutic doses, 0.5 mg and 1 mg, and will be launched in the OZEMPIC® pre-filled pen. The global Phase 3a clinical trial program for OZEMPIC® comprised eight clinical trials involving more than 8,000 adults with type 2 diabetes, including a two-year cardiovascular outcomes trial that evaluated safety in adults with type 2 diabetes at high risk of cardiovascular events. Novo Nordisk expects to launch OZEMPIC® in the U.S. in First Quarter 2018, with a goal of ensuring broad insurance coverage and patient access to the product. OZEMPIC® will be priced at parity to current weekly GLP-1 receptor agonists and will be offered with a savings card program to reduce co-pays for eligible commercially-insured patients. Additionally, as part of the access strategy, Novo Nordisk is working with appropriate health insurance providers to establish innovative contracting solutions.
Novo Nordisk, Inc. Presents at 10th Annual Biotech Showcase 2018, Jan-09-2018 08:00 AM
Nov 10 17
Novo Nordisk, Inc. Presents at 10th Annual Biotech Showcase 2018, Jan-09-2018 08:00 AM. Venue: Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, California, United States. Speakers: Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist, Innovation Sourcing.
Whistleblower Lawsuit Results in $1.1 Million Settlement with Novo Nordisk Inc
Sep 6 17
Insurance Commissioner Dave Jones reached a $1.1 million settlement with Novo Nordisk Inc. over allegations that Novo Nordisk's drug Victoza was extensively promoted for uses not approved of by the Food and Drug Administration, which violates the Insurance Frauds Prevention Action. The settlement stems from allegations in a whistleblower lawsuit filed by Peter Dastous, an Endocrinology Diabetes Care Specialist formerly employed by Novo Nordisk. Victoza was approved by the FDA for the treatment of adults with Type II diabetes. Dastous, represented by Phillips & Cohen, LLP, alleged Novo Nordisk inappropriately marketed Victoza for use with pediatric patients with Type II diabetes and adult patients who did not have Type II diabetes. The FDA did not approve the use of Victoza for the treatment of pediatric patients, due to the lack of pediatric studies. In approving Victoza, the FDA issued a warning that the medication had a risk of tumors caused by Medullary Thyroid Carcinoma (MTC). Victoza's marketing was inconsistent with the labeling instructions and warnings concerning the risk of MTC tumors. The settlement also addresses allegations that Novo Nordisk officials provided its sales force with information used to create a false or misleading impression, which minimized the importance of the FDA warning concerning the risk of tumors caused by MTC. Certain Novo Nordisk sales representatives allegedly made false or misleading statements designed to circumvent the requirements of the warning issued through the FDA.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|